Decriminalization of psychedelics is gaining traction in various states, paving the way for broader acceptance and research. While MDMA remains a Schedule One substance, its potential as a breakthrough medication is being explored through clinical studies at multiple universities. The conversation highlights the evolving landscape of psychedelic therapy and the importance of staying curious in the realm of medicine.
